Lanean...
Novel targets in aggressive lymphoma
Targeting CD20 with the monoclonal antibody rituximab has improved survival in patients with aggressive B-cell lymphomas, the majority of which are cured with chemoimmunotherapy. Patients progressing through or relapsing after their treatment have a poor prognosis. Despite a number of promising nove...
Gorde:
| Argitaratua izan da: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society of Hematology
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727526/ https://ncbi.nlm.nih.gov/pubmed/33275737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000093 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|